All In Biotech

Drug Trial Radar · NCT05826990

A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 11, 2023

Primary completion

May 21, 2029

Study completion May 21, 2029

Sponsor

Lead sponsor
Orchid Pharma Europe GmbHIndustry
Sponsor type
Industry
Collaborators
Innvocept Global Solutions Private Limited
First posted
Apr 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.

Conditions

  • Complicated Urinary Tract Infection

Interventions

  • cefepime and enmetazobactam combinationDrug

    Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics CmaxTime frame: Day 1 - Day 2
  2. Pharmacokinetics TmaxTime frame: Day 1 - Day 2
  3. Pharmacokinetics AUC0-tauTime frame: Day 1 - Day 2
  4. Pharmacokinetics AUC0-infTime frame: Day 1 - Day 2
  5. Pharmacokinetics t1/2Time frame: Day 1 - Day 2
  6. Pharmacokinetics CL & VdTime frame: Day 1 - Day 2
  7. Pharmacokinetics CminTime frame: Day 1 - Day 2
  8. Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
  9. Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
  10. Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
  11. Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
  12. Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)

Locations

8 sites in 6 countries. Site status is shown where the registry gives one.

  • Fakultní nemocnice Hradec Králové -Ústav klinické biochemie a diagnostiky

    Hradec Králové, Czechia · Withdrawn

  • Oblastni nemocnice Kolin, a.s., nemocnice Stredoceskeho kraje - Detske oddeleni

    Kolín, Czechia · Recruiting

  • Hopital des Enfants

    Toulouse, France · Withdrawn

  • Debreceni Egyetem Klinikai Központ Gyermekgyógyászati Klinika

    Debrecen, Hungary · Withdrawn

  • Kanizsai Dorottya Hospital

    Nagykanizsa, Hungary · Recruiting

  • SZPZOZ im. Dzieci Warszawy w Dziekanowie Leśnym

    Łomianki, Poland · Recruiting

  • Národný ústav detských chorôb (NÚDCH)

    Bratislava, Slovakia · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.